Jeffrey N. Fredman
109 IP cases indexed. Covers patent matters.
Cases Presided Over
109 cases indexed | Page 2 of 4
Imperative Care, Inc. v.Inari Medical, Inc.
The Board found that the claims were obvious over prior art references by combining known features to achieve a predictable result. Despite initial disputes over claim construction, the Petitioner failed to provide sufficient motivation for combining specific prior art elements.
Front Line Medical Technologies Inc. v.Prytime Medical Devices, Inc.
Petitioner successfully demonstrated that all ten challenged claims related to vascular occlusion catheters are unpatentable by a preponderance of the evidence. The Board relied heavily on various combinations of prior art references, primarily under 35 U.S.C. § 103 (obviousness).
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody challenged Hyperice's patent on percussive massagers based on indefiniteness and obviousness, but the PTAB upheld the claims. The Board found that key terms like 'substantially cylindrical' were supported by functional limitations in the specification.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
The PTAB instituted the IPR after finding a reasonable likelihood of success that the challenged claims are unpatentable based on obviousness (35 U.S.C. § 103). The Board analyzed key claim terms, preliminarily construing 'validated' as a negative test result rather than release into commerce.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully initiated an IPR against Institute for Environmental Health, Inc.'s microbial testing patent (8822143). The Board adopted a narrow definition of 'validated' as merely determining a sample tests negative using the detection assay.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully petitioned to institute IPR against the '771 patent, establishing a reasonable likelihood of success over at least one claim. The Board adopted Petitioner's definition for 'validation,' clarifying that it merely requires a sample test negative, rejecting the Patent Owner's broader interpretation regarding commercial release.
Dexcom, Inc. v.Abbott Diabetes Care Inc.
Dexcom successfully petitioned to institute an IPR against Abbott Diabetes Care Inc.'s glucose monitoring patent (11298056). The Board found a reasonable likelihood of prevailing on grounds of obviousness (103) for claims 13 and 29.
Vectair Systems Inc. v.Fresh Products, Inc.
Vectair Systems Inc.'s IPR challenge against Fresh Products, Inc.'s patent was denied by the PTAB. The Board found that the Petitioner failed to establish a reasonable likelihood of prevailing on grounds of anticipation (102) or obviousness (103).
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing Company successfully challenged claims 1-30 of the '486 patent in a PTAB Institution Decision, establishing a reasonable likelihood that the methods for pathogen detection are unpatentable. The petitioner relied on prior art references including Rayman and Nagar to demonstrate anticipation and obviousness across multiple grounds.
Imperative Care, Inc. v.INARI MEDICAL, INC.
Imperative Care, Inc. successfully challenged nine claims of INARI MEDICAL's hemostasis valve patent (11697011) at the PTAB. The Board found sufficient evidence for Petitioner’s anticipation challenge against Claim 1 after adopting a broad interpretation of the term 'filament.'
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied the institution of an IPR challenge against Inari Medical's patent (11744691) covering emboli treatment systems. The Board found that the petitioner, Imperative Care, Inc., failed to demonstrate a reasonable likelihood of prevailing on its grounds of anticipation and obviousness.
PreOmics GmbH et al. v.The Brigham and Women’s Hospital, Inc.
PreOmics GmbH et al. successfully petitioned for institution in the IPR against The Brigham and Women’s Hospital, Inc., challenging claims related to sensor arrays for protein corona analysis. The Board found a reasonable likelihood of unpatentability based on grounds of anticipation (102) and obviousness (103).
Aardevo North America, LLC et al. v.Agventure B.V.
The PTAB denied Aardevo North America's IPR petition against Agventure B.V., finding the petitioner failed to overcome compelling objective indicia of non-obviousness. The Board rejected arguments based on anticipation and obviousness, particularly concerning potato breeding methods.
Garmin International, Inc. v.Cardiacsense LTD
Garmin International successfully navigated the initial stages of its IPR challenge against Cardiacsense LTD's '998 patent, establishing a reasonable likelihood of prevailing on several grounds. The Board found that certain claims were not entitled to an earlier effective filing date due to insufficient written description support for a compass feature in prior applications.
Azurity Pharmaceuticals, Inc. v.EXELIXIS, INC.
Azurity Pharmaceuticals failed to convince the PTAB that EXELIXIS's drug formulation patent was unpatentable, resulting in a denial of institution for IPR2025-00210. The Board rejected anticipation arguments based on prior art family relationships and dismissed obviousness claims regarding impurity control.
Imperative Care, Inc. v.Inari Medical, Inc.
Imperative Care challenges Inari Medical's hemostasis valve patent (11554005) on obviousness grounds. The PTAB instituted the IPR, requiring further review of claims 1-15 based on prior art combinations.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB decided to institute trial on all challenged claims of the '921 patent, despite preliminary evidence not supporting anticipation over Schaffer. The Board adopted a broad definition of 'filament' but ultimately found that the claim language required flexibility based on intrinsic and extrinsic teachings.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB institution decision in this IPR found that the petitioner met its burden of showing a reasonable likelihood of prevailing on at least claim 1. The dispute centers on obviousness (35 U.S.C. § 103) regarding medical devices used for aspirating clot material from blood vessels.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully petitioned the PTAB against Halozyme, Inc.'s '298 patent covering modified PH20 polypeptides. The Board granted institution despite challenges based on Written Description and Enablement, allowing the dispute to proceed to trial.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s claims regarding modified PH20 polypeptides in a PTAB decision. The Board instituted trial based on enablement and written description grounds, finding that the broad genus of claimed molecules required undue experimentation to identify active variants.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
The PTAB instituted the PGR petition challenging Halozyme's patent covering modified PH20 polypeptides. The Board found that the claims were not sufficiently supported by the specification regarding enablement and obviousness, despite Petitioner's arguments about the genus size.
ITM Isotope Technologies Munich SE v.The Johns Hopkins University et al.
ITM Isotope Technologies Munich SE challenged The Johns Hopkins University's claims regarding FAP-α targeting moieties based on obviousness and patentability issues (103/112). The Board instituted the PGR, finding that the claims face significant challenges related to enablement and indefiniteness.
Therabody, Inc. v.Hyperice IP Subco, LLC et al.
Therabody successfully challenged Hyperice's patent claims in a PTAB proceeding focused on massaging devices. The Board found likelihood of unpatentability based on obviousness and statutory deficiencies, particularly regarding the combination of prior art references.
Merck Sharp & Dohme LLC v.Halozyme, Inc. et al.
Merck Sharp & Dohme LLC successfully challenged Halozyme, Inc.'s patent on enablement and obviousness grounds in a PTAB decision. The Board found that the patent documents supported a broad definition of modified PH20 polypeptides, while noting the petitioner had established a likelihood of prevailing on enablement but failed to prove obviousness.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef Packing and Institute for Environmental Health settled their inter partes review of U.S. Patent 7,534,584. The Board terminated the proceeding without a merits decision, granting confidentiality for the settlement.
National Beef Packing Company, LLC v.Institute for Environmental Health, Inc.
National Beef and Institute for Environmental Health settled four inter partes reviews covering patents 7,534,584; 8,822,143; 9,637,771; and 9,845,486. The Board terminated the proceedings based on a written settlement agreement and granted confidentiality for the agreement.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB denied Imperative Care’s petition to institute an IPR against Inari Medical’s U.S. Patent 11,744,691, finding no reasonable likelihood of success. The Board concluded the cited prior art did not disclose the required negative‑pressure pump configuration.
Imperative Care, Inc. v.Inari Medical, Inc.
The PTAB instituted an inter partes review of Inari Medical’s 11,697,011 B2 hemostasis valve patent after finding Imperative Care’s likelihood of success on at least one claim.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB denied Imperative Care’s petition to review Inari Medical’s 11,744,691 patent covering catheter‑based embolism removal. The Board found the petitioner had not shown a reasonable likelihood of prevailing on any of the 31 challenged claims.
Imperative Care, Inc. v.Inari Medical, Inc. et al.
The PTAB instituted an inter partes review of Inari Medical’s U.S. Patent 12,016,580 covering intravascular embolism treatment devices after finding Imperative Care’s obviousness arguments sufficiently promising.
Facing a similar IP matter?
Arctic Invent is a specialist IP firm with deep litigation expertise across India, EU, US, and UK. Our team uses data-driven strategy to build stronger cases.